Predictability of hematopoietic stem cell transplantation rates

被引:30
作者
Gratwohl, Alois [1 ]
Baldomero, Helen [1 ]
Schwendener, Alvin [2 ]
Gratwohl, Michael [1 ]
Apperley, Jane [3 ]
Niederwieser, Dietger [4 ]
Frauendorfer, Karl [2 ]
机构
[1] Univ Hosp Basel, Dept Med, Hematol, Basel, Switzerland
[2] Univ St Gallen, Inst Operat Res & Computat Finance, St Gallen, Switzerland
[3] Hammersmith Hosp, Hematol, London, England
[4] Univ Leipzig, Hematol & Oncol, Leipzig, Germany
基金
新加坡国家研究基金会;
关键词
predictability; HSCT rates;
D O I
10.3324/haematol.11260
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives Hematopoietic stem cell transplantation (HSCT) is a complex and expensive procedure. Trends in the use of this procedure have appeared erratic in the past. Information on future needs is essential for health care administrators. Design and Methods We analyzed the evolution of transplant rates, e.g. numbers of transplants per 10 million inhabitants, in Europe from 1990 to 2004 for all major disease categories and used Gross National Income (GNI) per capita, team density (numbers of teams per 10 million inhabitants) and team distribution (numbers of teams per 10,000 km(2)) to measure the impact of economic factors in participating countries. Trends were compared by regression analyses, and countries were grouped by World Bank definitions into high, middle and low income categories. Results Transplant rates increased over time with nearly linear trends, in clear association with GNI per capita (R-2=0.72), and distinct by World Bank category within a narrow window of variation for both autologous HSCT (R-2 =0.95, 0.98 and 0.94 for high, middle and low income categories, respectively) and allogeneic HSCT (R-2=0.99, 0.96 and 0.95 for high, middle and low income categories, respectively) when breast cancer (autologous) and chronic myeloid leukemia (allogeneic) were excluded. Team density (R-2=0.72) and team distribution (R-2 =0.51) were also associated with transplant rates. Interpretation and Conclusions Transplant rates for HSCT in Europe are highly predictable. They are primarily influenced by GNI per capita. The absence of saturation and a nearly linear trend indicate that infrastructure lags behind medical needs. Isolated changes in single disease entities can easily be recognized.
引用
收藏
页码:1679 / 1686
页数:8
相关论文
共 29 条
[1]   Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet [J].
Baccarani, Michele ;
Saglio, Giuseppe ;
Goldman, John ;
Hochhaus, Andreas ;
Simonsson, Bengt ;
Appelbaum, Frederick ;
Apperley, Jane ;
Cervantes, Francisco ;
Cortes, Jorge ;
Deininger, Michael ;
Gratwohl, Alois ;
Guilhot, Frangois ;
Horowitz, Mary ;
Hughes, Timothy ;
Kantarjian, Hagop ;
Larson, Richard ;
Niederwieser, Dielger ;
Silver, Richard ;
Hehlmann, Rudiger .
BLOOD, 2006, 108 (06) :1809-1820
[2]   The importance of lowering the costs of stem cell transplantation in developing countries [J].
Barr, RD .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2002, 76 (Suppl 1) :365-367
[3]   Medical progress: Hematopoietic stem-cell transplantation [J].
Copelan, EA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (17) :1813-1826
[4]  
Dalziel K, 2004, HEALTH TECHNOL ASSES, V8, P1
[5]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[6]   Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].
Druker, Brian J. ;
Guilhot, Francois ;
O'Brien, Stephen G. ;
Gathmann, Insa ;
Kantarjian, Hagop ;
Gattermann, Norbert ;
Deininger, Michael W. N. ;
Silver, Richard T. ;
Goldman, John M. ;
Stone, Richard M. ;
Cervantes, Francisco ;
Hochhaus, Andreas ;
Powell, Bayard L. ;
Gabrilove, Janice L. ;
Rousselot, Philippe ;
Reiffers, Josy ;
Cornelissen, Jan J. ;
Hughes, Timothy ;
Agis, Hermine ;
Fischer, Thomas ;
Verhoef, Gregor ;
Shepherd, John ;
Saglio, Giuseppe ;
Gratwohl, Alois ;
Nielsen, Johan L. ;
Radich, Jerald P. ;
Simonsson, Bengt ;
Taylor, Kerry ;
Baccarani, Michele ;
So, Charlene ;
Letvak, Laurie ;
Larson, Richard A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417
[7]   Do affluent societies have the only options for the best therapy? [J].
Gajewski, J. L. ;
Robinson, P. .
LEUKEMIA, 2007, 21 (03) :387-388
[8]   Blood and marrow transplantation compensation: Perspective in payer and provider relations [J].
Gajewski, JL ;
Foote, M ;
Tietjen, J ;
Melson, B ;
Simmons, A ;
Champlin, RE .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (07) :427-432
[9]   Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe - Impact of cost considerations [J].
Gratwohl, A. ;
Baldomero, H. ;
Schwendener, A. ;
Gratwohl, M. ;
Urbano-Ispizua, A. ;
Frauendorfer, K. .
LEUKEMIA, 2007, 21 (03) :383-386
[10]   EBMT activity survey 2004 and changes in disease indication over the past 15 years [J].
Gratwohl, A. ;
Baldomero, H. ;
Frauendorfer, K. ;
Urbano-Ispizua, A. .
BONE MARROW TRANSPLANTATION, 2006, 37 (12) :1069-1085